pentoxifylline has been researched along with Proteinuria in 44 studies
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have conducted a double blinded clinical trial to assess the additive effect of pentoxifylline on reduction of proteinuria among patients with type 2 DM under blockade of angiotensin system." | 9.16 | The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. ( Beladi-Mousavi, SS; Ghorbani, A; Lak, E; Omidvar, B; Vaziri, S, 2012) |
| "Pentoxifylline may decrease proteinuria in non-diabetic patients with CKD." | 9.14 | Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study. ( Aleksandrowicz, E; Knap, N; Neuwelt, A; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Woźniak, M; Zietkiewicz, M; Łysiak-Szydłowska, W, 2010) |
| " In the first stage, pentoxifylline decreased median proteinuria from 1,140 to 800 mg/g (median change, -23." | 9.13 | Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. ( Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ; Wu, KD, 2008) |
| "This study demonstrates that treatment with PTX and captopril both significantly reduce overt proteinuria in patients with type 2 diabetes." | 9.11 | Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus. ( Amini, M; Aminian, T; Aminorroaya, A; Gharavi, M; Janghorbani, M; Rezvanian, H, 2005) |
| "We searched bibliographic databases for trials involving pentoxifylline that reported proteinuria, glomerular filtration rate, or blood pressure." | 8.84 | The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. ( Akbari, A; Doucette, S; Fergusson, D; Knoll, G; McCormick, BB; Sydor, A, 2008) |
| "To evaluate the efficacy of pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis." | 7.72 | Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis. ( Aviña-Zubieta, JA; Bustamante, R; Esquivel-Nava, G; Galindo-Rodríguez, G; Salazar-Exaire, D; Vadillo-Buenfil, M; Vela-Ojeda, J, 2003) |
| "In 1985, investigators reported that four months of pentoxifylline therapy resulted in a significant decrease in proteinuria (46 percent reduction) and plasma fibrinogen concentrations (18 percent reduction) in patients with diabetes." | 7.68 | Effects of pentoxifylline on proteinuria in normotensive patients with diabetes mellitus. ( Karam, JH; Koda-Kimble, MA; White, JR, 1990) |
| "Treatment with pentoxifylline for 6 months resulted in a significant reduction of mean UPE (p < 0." | 6.78 | Effect of add-on pentoxifylline on proteinuria in membranous glomerulonephritis: a 6-month placebo-controlled trial. ( Abbasi, MR; Ahmadi, F; Badri, S; Dashti-Khavidaki, S; Khalili, H; Mahdavi-Mazdeh, M, 2013) |
| "Forty-one patients with IDDM were stratified in 2 subgroups: one of 18 patients with microalbuminuria, and the other of 23 patients with overt proteinuria." | 6.68 | Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. ( Amato, D; García-Bulnes, G; Guerrero-Romero, F; Paniagua-Sierra, JR; Rodríguez-Morán, M; Salas-Ramírez, M, 1995) |
| " Conclusion of this review is that short-term use of PTF may produce a significant reduction of proteinuria in subjects with diabetic and also non-diabetic kidney diseases but the reports of long-term use of PTF also show that urinary protein excretion exhibits a progressive and sustained reduction in patients treated with PTF." | 6.47 | A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria. ( Abdollahi, M; Badri, S; Dashti-Khavidaki, S; Lessan-Pezeshki, M, 2011) |
| "Anti-Thy1 glomerulonephritis is a rat nephritis model closely simulating human mesangial proliferative glomerulonephritis." | 5.42 | Pentoxifylline Attenuates Proteinuria in Anti-Thy1 Glomerulonephritis via Downregulation of Nuclear Factor-κB and Smad2/3 Signaling. ( Chen, YM; Chiang, WC; Lai, CF; Lin, SL; Wu, KD; Yang, Y, 2015) |
| "Proteinuria was diagnosed in 2003 (DPE 3." | 5.35 | [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline]. ( Larczyński, W; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Zietkiewicz, M, 2008) |
| "Pentoxifylline (PTX) is a phosphodiesterase inhibitor that possesses potent anti-inflammatory and immunomudulatory effects." | 5.33 | Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. ( Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ; Wu, KD, 2006) |
| "Crescentic glomerulonephritis is a rapidly progressive form of glomerulonephritis, but treatment remains non-specific." | 5.32 | Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats. ( Chen, YM; Chiang, WC; Lan, HY; Lin, SL; Ng, YY; Tsai, TJ, 2004) |
| " We have conducted a double blinded clinical trial to assess the additive effect of pentoxifylline on reduction of proteinuria among patients with type 2 DM under blockade of angiotensin system." | 5.16 | The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. ( Beladi-Mousavi, SS; Ghorbani, A; Lak, E; Omidvar, B; Vaziri, S, 2012) |
| "Pentoxifylline may decrease proteinuria in non-diabetic patients with CKD." | 5.14 | Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study. ( Aleksandrowicz, E; Knap, N; Neuwelt, A; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Woźniak, M; Zietkiewicz, M; Łysiak-Szydłowska, W, 2010) |
| " In the first stage, pentoxifylline decreased median proteinuria from 1,140 to 800 mg/g (median change, -23." | 5.13 | Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. ( Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ; Wu, KD, 2008) |
| "This study demonstrates that treatment with PTX and captopril both significantly reduce overt proteinuria in patients with type 2 diabetes." | 5.11 | Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus. ( Amini, M; Aminian, T; Aminorroaya, A; Gharavi, M; Janghorbani, M; Rezvanian, H, 2005) |
| "The aim of this study was to assess the effect of pentoxifylline on proteinuria and renal function in chronic kidney disease (CKD) treatment." | 4.93 | Effect of pentoxifylline in proteinuric chronic kidney disease: a systematic review and meta-analysis. ( Cui, M; Jiang, X; Kong, X; Yao, J; Zhou, S, 2016) |
| "To determine if there is sufficient evidence to recommend the addition of pentoxifylline to standard ACE inhibitor and ARB therapy in chronic kidney disease patients to reduce proteinuria and preserve kidney function." | 4.93 | Can Pentoxifylline be used as Adjunct Therapy to ACE Inhibitors and ARBs in Preserving Kidney Function? ( Al-Makki, A; Carson, C; Shepler, B, 2016) |
| "From the available evidence, pentoxifylline seems to offer some beneficial effects in renal function improvement and reduction in albuminuria and proteinuria, with no obvious serious adverse effects for patients with DKD." | 4.88 | Pentoxifylline for diabetic kidney disease. ( Li, J; Liu, GJ; Shan, D; Wu, HM; Yuan, QY; Zhou, RL, 2012) |
| "We searched bibliographic databases for trials involving pentoxifylline that reported proteinuria, glomerular filtration rate, or blood pressure." | 4.84 | The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. ( Akbari, A; Doucette, S; Fergusson, D; Knoll, G; McCormick, BB; Sydor, A, 2008) |
| " The present study compares the effects of the cGMP production-increasing soluble guanylate cyclase (sGC) stimulator BAY 41-2272 with those of the cGMP degradation-limiting phosphodiesterase inhibitor pentoxifylline (PTX) in a progressive model of renal fibrosis." | 3.73 | Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition. ( Kawachi, H; Krämer, S; Kron, S; Loof, T; Martini, S; Neumayer, HH; Peters, H; Shimizu, F; Wang, Y, 2006) |
| " Modification of the Th1/Th2 ratio during induction with preparations acting on the immune system cells via different mechanisms and shifting the Th1/Th2 balance towards Th2 (bisphenol A, pentoxifylline, muramyl dipeptide) increases the incidence of Th2-dependent autoimmune lupus-like glomerulonephritis." | 3.73 | Effects of preparations modifying Th1/Th2 ratio on the incidence of clinical variants of chronic graft-versus-host reaction. ( Goiman, EV; Kolesnikova, OP; Kozlov, VA; Kudaeva, OT; Lykov, AP, 2005) |
| "To evaluate the efficacy of pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis." | 3.72 | Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis. ( Aviña-Zubieta, JA; Bustamante, R; Esquivel-Nava, G; Galindo-Rodríguez, G; Salazar-Exaire, D; Vadillo-Buenfil, M; Vela-Ojeda, J, 2003) |
| "In 1985, investigators reported that four months of pentoxifylline therapy resulted in a significant decrease in proteinuria (46 percent reduction) and plasma fibrinogen concentrations (18 percent reduction) in patients with diabetes." | 3.68 | Effects of pentoxifylline on proteinuria in normotensive patients with diabetes mellitus. ( Karam, JH; Koda-Kimble, MA; White, JR, 1990) |
| "Treatment with pentoxifylline for 6 months resulted in a significant reduction of mean UPE (p < 0." | 2.78 | Effect of add-on pentoxifylline on proteinuria in membranous glomerulonephritis: a 6-month placebo-controlled trial. ( Abbasi, MR; Ahmadi, F; Badri, S; Dashti-Khavidaki, S; Khalili, H; Mahdavi-Mazdeh, M, 2013) |
| "Pentoxifylline is a nonspecific phosphodiesterase inhibitor with anti-inflammatory properties." | 2.74 | Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. ( Aboudara, MC; Cushner, HM; Olson, SW; Perkins, RM; Uy, AL; Yuan, CM, 2009) |
| "In 45 patients with type 2 diabetes mellitus (DM), we prospectively analyzed urinary excretion of N-acetyl-beta-glucosaminidase (NAG), a marker of tubular renal damage; the potential relationship with urinary protein excretion; and effects of pentoxifylline (PTF) administration." | 2.71 | Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study. ( Garca, J; Maca, M; Mora, C; Muros, M; Navarro, JF, 2003) |
| "Forty-one patients with IDDM were stratified in 2 subgroups: one of 18 patients with microalbuminuria, and the other of 23 patients with overt proteinuria." | 2.68 | Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. ( Amato, D; García-Bulnes, G; Guerrero-Romero, F; Paniagua-Sierra, JR; Rodríguez-Morán, M; Salas-Ramírez, M, 1995) |
| "Posttransplantation proteinuria is associated with reduced graft survival as well as an increased risk of cardiovascular events and death." | 2.52 | Evaluation and Management of Proteinuria After Kidney Transplantation. ( Knoll, GA; Tsampalieros, A, 2015) |
| " Conclusion of this review is that short-term use of PTF may produce a significant reduction of proteinuria in subjects with diabetic and also non-diabetic kidney diseases but the reports of long-term use of PTF also show that urinary protein excretion exhibits a progressive and sustained reduction in patients treated with PTF." | 2.47 | A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria. ( Abdollahi, M; Badri, S; Dashti-Khavidaki, S; Lessan-Pezeshki, M, 2011) |
| "Anti-Thy1 glomerulonephritis is a rat nephritis model closely simulating human mesangial proliferative glomerulonephritis." | 1.42 | Pentoxifylline Attenuates Proteinuria in Anti-Thy1 Glomerulonephritis via Downregulation of Nuclear Factor-κB and Smad2/3 Signaling. ( Chen, YM; Chiang, WC; Lai, CF; Lin, SL; Wu, KD; Yang, Y, 2015) |
| "Systemic lupus erythematosus is a polymorphic and multigenic inflammatory autoimmune disease." | 1.38 | Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor. ( Bourguignon, JJ; Gazi, L; Keravis, T; Lugnier, C; Monneaux, F; Muller, S; Yougbaré, I, 2012) |
| "Proteinuria was diagnosed in 2003 (DPE 3." | 1.35 | [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline]. ( Larczyński, W; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Zietkiewicz, M, 2008) |
| "Pentoxifylline (PTX) is a phosphodiesterase inhibitor that possesses potent anti-inflammatory and immunomudulatory effects." | 1.33 | Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. ( Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ; Wu, KD, 2006) |
| "Crescentic glomerulonephritis is a rapidly progressive form of glomerulonephritis, but treatment remains non-specific." | 1.32 | Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats. ( Chen, YM; Chiang, WC; Lan, HY; Lin, SL; Ng, YY; Tsai, TJ, 2004) |
| "A long-term trial with oral pentoxifylline ("Trental" 400) in a dosage of 1200 mg per day was carried out in 70 diabetic patients with and without vascular afflictions." | 1.27 | Diabetic retinal vascular complications and erythrocyte filtrability; results of a 2-year follow-up study with pentoxifylline. ( Ferrari, E; Solerte, SB, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.55) | 18.7374 |
| 1990's | 9 (20.45) | 18.2507 |
| 2000's | 17 (38.64) | 29.6817 |
| 2010's | 16 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YM | 8 |
| Chiang, WC | 7 |
| Lin, SL | 6 |
| Tsai, TJ | 6 |
| Kao, CC | 1 |
| Wu, MS | 2 |
| Yang, Y | 1 |
| Lai, CF | 2 |
| Wu, KD | 4 |
| Tsampalieros, A | 1 |
| Knoll, GA | 1 |
| Jiang, X | 1 |
| Zhou, S | 1 |
| Yao, J | 1 |
| Kong, X | 1 |
| Cui, M | 1 |
| Lai, TS | 1 |
| Leporini, C | 1 |
| Pisano, A | 1 |
| Russo, E | 1 |
| D Arrigo, G | 1 |
| de Sarro, G | 1 |
| Coppolino, G | 1 |
| Bolignano, D | 1 |
| Carson, C | 1 |
| Al-Makki, A | 1 |
| Shepler, B | 1 |
| Renke, M | 2 |
| Rutkowski, P | 2 |
| Tylicki, L | 2 |
| Zietkiewicz, M | 2 |
| Larczyński, W | 1 |
| Rutkowski, B | 2 |
| Perkins, RM | 1 |
| Aboudara, MC | 1 |
| Uy, AL | 1 |
| Olson, SW | 1 |
| Cushner, HM | 1 |
| Yuan, CM | 1 |
| Han, KH | 1 |
| Han, SY | 1 |
| Kim, HS | 1 |
| Kang, YS | 1 |
| Cha, DR | 1 |
| Roozbeh, J | 1 |
| Banihashemi, MA | 1 |
| Ghezlou, M | 1 |
| Afshariani, R | 1 |
| Salari, S | 1 |
| Moini, M | 1 |
| Sagheb, MM | 1 |
| Knap, N | 1 |
| Neuwelt, A | 1 |
| Aleksandrowicz, E | 1 |
| Łysiak-Szydłowska, W | 1 |
| Woźniak, M | 1 |
| Badri, S | 2 |
| Dashti-Khavidaki, S | 2 |
| Lessan-Pezeshki, M | 1 |
| Abdollahi, M | 1 |
| Keravis, T | 1 |
| Monneaux, F | 1 |
| Yougbaré, I | 1 |
| Gazi, L | 1 |
| Bourguignon, JJ | 1 |
| Muller, S | 1 |
| Lugnier, C | 1 |
| Shan, D | 1 |
| Wu, HM | 1 |
| Yuan, QY | 1 |
| Li, J | 1 |
| Zhou, RL | 1 |
| Liu, GJ | 1 |
| Ghorbani, A | 1 |
| Omidvar, B | 1 |
| Beladi-Mousavi, SS | 1 |
| Lak, E | 1 |
| Vaziri, S | 1 |
| Ahmadi, F | 1 |
| Mahdavi-Mazdeh, M | 1 |
| Abbasi, MR | 1 |
| Khalili, H | 1 |
| Navarro, JF | 4 |
| Mora, C | 4 |
| Muros, M | 2 |
| Maca, M | 1 |
| Garca, J | 1 |
| Galindo-Rodríguez, G | 1 |
| Bustamante, R | 1 |
| Esquivel-Nava, G | 1 |
| Salazar-Exaire, D | 1 |
| Vela-Ojeda, J | 1 |
| Vadillo-Buenfil, M | 1 |
| Aviña-Zubieta, JA | 1 |
| Ng, YY | 1 |
| Lan, HY | 1 |
| Banfi, C | 1 |
| Sironi, L | 1 |
| De Simoni, G | 1 |
| Gelosa, P | 1 |
| Barcella, S | 1 |
| Perego, C | 1 |
| Gianazza, E | 1 |
| Guerrini, U | 1 |
| Tremoli, E | 1 |
| Mussoni, L | 1 |
| Usta, Y | 1 |
| Ismailoglu, UB | 1 |
| Bakkaloglu, A | 1 |
| Orhan, D | 1 |
| Besbas, N | 1 |
| Sahin-Erdemli, I | 1 |
| Ozen, S | 1 |
| Aminorroaya, A | 1 |
| Janghorbani, M | 1 |
| Rezvanian, H | 1 |
| Aminian, T | 1 |
| Gharavi, M | 1 |
| Amini, M | 1 |
| Hsieh, BS | 1 |
| García, J | 2 |
| Wang, Y | 1 |
| Krämer, S | 1 |
| Loof, T | 1 |
| Martini, S | 1 |
| Kron, S | 1 |
| Kawachi, H | 1 |
| Shimizu, F | 1 |
| Neumayer, HH | 1 |
| Peters, H | 1 |
| Kudaeva, OT | 1 |
| Goiman, EV | 1 |
| Lykov, AP | 1 |
| Kolesnikova, OP | 1 |
| Kozlov, VA | 1 |
| Rodriguez-Morán, M | 2 |
| González-González, G | 1 |
| Bermúdez-Barba, MV | 1 |
| Medina de la Garza, CE | 1 |
| Tamez-Pérez, HE | 1 |
| Martínez-Martínez, FJ | 1 |
| Guerrero-Romero, F | 2 |
| McCormick, BB | 1 |
| Sydor, A | 1 |
| Akbari, A | 1 |
| Fergusson, D | 1 |
| Doucette, S | 1 |
| Knoll, G | 1 |
| Paniagua-Sierra, JR | 1 |
| García-Bulnes, G | 1 |
| Salas-Ramírez, M | 1 |
| Amato, D | 1 |
| Hecht, M | 1 |
| Müller, M | 1 |
| Lohmann-Matthes, ML | 1 |
| Emmendörffer, A | 1 |
| Tripathi, K | 1 |
| Prakash, J | 1 |
| Appaiha, D | 1 |
| Srivastava, PK | 1 |
| Steinmann-Niggli, K | 1 |
| Ziswiler, R | 1 |
| Küng, M | 1 |
| Marti, HP | 1 |
| Gorson, DM | 1 |
| Rivero, A | 1 |
| Gallego, E | 1 |
| Chahin, J | 1 |
| Macía, M | 1 |
| Méndez, ML | 1 |
| Chien, CT | 1 |
| Hu-Tsai, MI | 1 |
| Tsai, CC | 1 |
| Ducloux, D | 1 |
| Bresson-Vautrin, C | 1 |
| Chalopin, J | 1 |
| White, JR | 1 |
| Karam, JH | 1 |
| Koda-Kimble, MA | 1 |
| Solerte, SB | 2 |
| Adamo, S | 1 |
| Viola, C | 1 |
| Zambianchi, E | 1 |
| Ferrari, E | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pentoxifylline and Progression of Chronic Kidney Disease in Moderate-to-high Risk Patients: a Pilot Randomized, Placebo-controlled, Double-blind Trial.[NCT00285298] | Phase 3 | 39 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for pentoxifylline and Proteinuria
| Article | Year |
|---|---|
Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update.
Topics: Disease Progression; Kidney Failure, Chronic; Pentoxifylline; Phosphodiesterase Inhibitors; Proteinu | 2017 |
Evaluation and Management of Proteinuria After Kidney Transplantation.
Topics: Angiotensin Receptor Antagonists; Biopsy; Blood Pressure; Female; Graft Survival; Humans; Immunosupp | 2015 |
Effect of pentoxifylline in proteinuric chronic kidney disease: a systematic review and meta-analysis.
Topics: Chi-Square Distribution; Glomerular Filtration Rate; Humans; Kidney; Odds Ratio; Pentoxifylline; Pho | 2016 |
Effect of pentoxifylline on renal outcomes in chronic kidney disease patients: A systematic review and meta-analysis.
Topics: Humans; Kidney; Pentoxifylline; Proteinuria; Randomized Controlled Trials as Topic; Renal Insufficie | 2016 |
Can Pentoxifylline be used as Adjunct Therapy to ACE Inhibitors and ARBs in Preserving Kidney Function?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellit | 2016 |
A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria.
Topics: Animals; Chronic Disease; Diabetic Nephropathies; Disease Progression; Humans; Kidney Diseases; Kidn | 2011 |
Pentoxifylline for diabetic kidney disease.
Topics: Albuminuria; Anti-Inflammatory Agents, Non-Steroidal; Diabetic Nephropathies; Humans; Pentoxifylline | 2012 |
The renoprotective potential of pentoxifylline in chronic kidney disease.
Topics: Cell Proliferation; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Pentoxifylline; Phospho | 2005 |
The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Diabetic Nephropat | 2008 |
13 trials available for pentoxifylline and Proteinuria
| Article | Year |
|---|---|
Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Chemokine CCL2; | 2008 |
Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Chronic Dis | 2009 |
Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy.
Topics: Adult; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chi-Square D | 2010 |
Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.
Topics: Adolescent; Adult; Aged; Blood Pressure; Cross-Over Studies; Female; Humans; Kidney Failure, Chronic | 2010 |
The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Humans; Male; Middle | 2012 |
Effect of add-on pentoxifylline on proteinuria in membranous glomerulonephritis: a 6-month placebo-controlled trial.
Topics: Adult; Female; Glomerulonephritis, Membranous; Humans; Male; Middle Aged; Pentoxifylline; Placebos; | 2013 |
Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study.
Topics: Acetylglucosaminidase; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diabetes Mellitus, Type 2; Dia | 2003 |
Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Captopril; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Femal | 2005 |
Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dr | 2005 |
Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Humans; | 2006 |
Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients.
Topics: Adult; Albuminuria; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Do | 1995 |
Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration.
Topics: Aged; Diabetic Nephropathies; Female; Humans; Male; Middle Aged; Pentoxifylline; Prospective Studies | 1999 |
[Pentoxifylline and arterial hypertension in diabetes mellitus: long-term results in randomized groups].
Topics: Diabetes Complications; Erythrocyte Deformability; Follow-Up Studies; Humans; Hypertension; Pentoxif | 1985 |
22 other studies available for pentoxifylline and Proteinuria
| Article | Year |
|---|---|
Renoprotective effect of pentoxifylline in advanced chronic kidney disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropathies; | 2015 |
Pentoxifylline Attenuates Proteinuria in Anti-Thy1 Glomerulonephritis via Downregulation of Nuclear Factor-κB and Smad2/3 Signaling.
Topics: Anaplastic Lymphoma Kinase; Animals; Cytokines; Disease Models, Animal; Gene Expression; Glomerulone | 2015 |
Pentoxifylline: Evidence strong enough for renoprotection?
Topics: Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Pentoxifylline; Phosphodiesterase Inhibitor | 2016 |
[Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type | 2008 |
Prolonged administration enhances the renoprotective effect of pentoxifylline via anti-inflammatory activity in streptozotocin-induced diabetic nephropathy.
Topics: Animals; Anti-Inflammatory Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Chemokin | 2010 |
Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor.
Topics: Adenine; Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Progression; Fem | 2012 |
Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Cyclophosphamide; Dose-Response Relationship, | 2003 |
Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats.
Topics: Animals; Disease Models, Animal; DNA Primers; Glomerulonephritis; Macrophages; Male; Pentoxifylline; | 2004 |
Pentoxifylline prevents spontaneous brain ischemia in stroke-prone rats.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Inflammation; Male; Pentoxifylline; Proteinuria; Ra | 2004 |
Effects of pentoxifylline in adriamycin-induced renal disease in rats.
Topics: Animals; Apoptosis; Doxorubicin; Kidney Diseases; Pentoxifylline; Proteinuria; Rats; Rats, Wistar; T | 2004 |
Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition.
Topics: Animals; Blood Pressure; Body Weight; Cell Proliferation; Cyclic GMP; Drinking; Fibrosis; Glomerulon | 2006 |
Effects of preparations modifying Th1/Th2 ratio on the incidence of clinical variants of chronic graft-versus-host reaction.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Anti-Glomerular Basement Membrane Disease; Benzhydryl Co | 2005 |
Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Chemokine CCL2; Creatinine; Cytokines; Female; Glomerul | 2006 |
In vitro and in vivo effects of pentoxifylline on macrophages and lymphocytes derived from autoimmune MRL-lpr/lpr mice.
Topics: Animals; Autoantibodies; Autoimmune Diseases; Autoimmunity; B-Lymphocytes; DNA; Female; Histocompati | 1995 |
Pentoxifylline in management of proteinuria in diabetic nephropathy.
Topics: Diabetic Nephropathies; Glomerular Filtration Rate; Humans; Pentoxifylline; Proteinuria | 1993 |
Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis.
Topics: Animals; Benzyl Compounds; Cell Count; Cells, Cultured; Creatinine; Dexamethasone; Drug Combinations | 1998 |
Reduction of macroalbuminuria with pentoxifylline in diabetic nephropathy. Report of three cases.
Topics: Aged; Aged, 80 and over; Albuminuria; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic | 1998 |
Antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy.
Topics: Albuminuria; Diabetic Nephropathies; Humans; Pentoxifylline; Proteinuria; Tumor Necrosis Factor-alph | 1999 |
Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis.
Topics: Animals; Antibodies, Monoclonal; Base Sequence; Cell Division; Chemokine CCL2; Collagen; Disease Mod | 1999 |
Use of pentoxifylline in membranous nephropathy.
Topics: Adult; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerulonephritis, Membranous; Humans; | 2001 |
Effects of pentoxifylline on proteinuria in normotensive patients with diabetes mellitus.
Topics: Adult; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fibrino | 1990 |
Diabetic retinal vascular complications and erythrocyte filtrability; results of a 2-year follow-up study with pentoxifylline.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopath | 1985 |